Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 6/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 6/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19406683 | 0.90 | MEN1 (0.35) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL5490052 | 0.86 | ALDH1A1 (0.47) | MEN1KMT2ATDP1CA1CA2 | |
| SCHEMBL3486013 | 0.86 | ALDH1A1 (0.47) | MEN1KMT2ATDP1CA1CA2 | |
| SCHEMBL992117 | 0.86 | ALDH1A1 (0.47) | MEN1KMT2ATDP1CA1CA2 | |
| SCHEMBL17445245 | 0.85 | MAOA (0.42) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL11569592 | 0.84 | EPHX1 (0.46) | GAACTSKMAOBCTSS | |
| SCHEMBL25142486 | 0.81 | MEN1 (0.37) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL21189283 | 0.81 | BLM (0.33) | MEN1GAAKMT2ACA1CA7 | |
| SCHEMBL21189165 | 0.81 | BLM (0.33) | MEN1GAAKMT2ACA1CA7 | |
| SCHEMBL21189288 | 0.81 | BLM (0.33) | MEN1GAAKMT2ACA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160160206-A1 | Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use | CATALENT PHARMA SOLUTIONS, LLC | 2016-06-09 | — | — | US | disclosed |
| US-9238878-B2 | Aldehyde-tagged protein-based drug carriers and methods of use | REDWOOD BIOSCIENCE, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-7964687-B2 | reacting methacrylic anhydride in chloroform with ethylenedioxy/bis/ethyleneamine, to form intermediate, reacting with tert-butyloxycarboyl-aminoacetic acid and carbodiminde compound to from monomer; homo or copolymerizing monomer with ethylene glycol, dimethacryalate crosslinker, deblocking polymer | SUMITOMO BAKELITE COMPANY, LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100210543-A1 | Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use | REDWOOD BIOSCIENCE, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20080097061-A1 | Oxylamino Group-Containing Compound and Polymer | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210543-A1 | Aldehyde-Tagged Protein-Based Drug Carriers and Methods of Use | ALDH3A1, ALDH1A1, ALDH2 | MEN1 4715/4885GAA 170/4885KMT2A 3332/4885 |
| US-20080097061-A1 | Oxylamino Group-Containing Compound and Polymer | MAOB, OPRM1, OXER1 | MEN1 3323/4885GAA 2366/4885KMT2A 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.